Department of Clinical Immunology, Oxford University Foundation Hospitals NHS Trust, Oxford, United Kingdom.
Department of Allergy and Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Front Immunol. 2019 May 29;10:1117. doi: 10.3389/fimmu.2019.01117. eCollection 2019.
Patients with suspected peri-operative anaphylaxis (POP) require thorough investigation to identify underlying trigger(s) and enable safe anesthesia for subsequent surgery. The changing epidemiology of POP has been striking. Previous estimates of the incidence of POP have ranged between 1:6,000 and1:20,000 anesthetics, but more recent data from France and the United Kingdom suggest an estimated incidence of 1:10,000. Other important changes include a change in the hierarchy of well-recognized triggers, with antibiotics (beta-lactams) supplanting neuromuscular blockers (NMB) as the leading cause of POP. The emergence of chlorhexidine, patent blue dye, and teicoplanin as important triggers have also been noteworthy findings. The mainstay of investigation revolves around critical analysis of the time-line of events leading up to anaphylaxis coupled with judicious skin testing. Skin tests have limitations with respect to unknown predictive values for most drugs/agents and therefore, knowledge of background positivity in healthy controls, test characteristics of individual drugs and the use of non-irritant concentrations is essential to avoid both false-positive and false-negative results. Specific IgE assays for individual drugs are available only for a limited number of agents and are not a substitute for skin testing. Acute serum total tryptase has a high specificity and positive predictive value in IgE-mediated POP anaphylaxis but is limited by its moderate sensitivity and negative predictive value. Planning for safe anesthesia in this group of patients is particularly challenging and consequently anesthetists need to be alert to the possibility of repeat episodes of anaphylaxis. Because of the limitations of current investigations for POP, collecting systematic data on the outcome of repeat anesthesia is valuable in validating current investigatory approaches. This paper reviews the changing epidemiology of POP with reference to the main triggers, and the investigation and outcome of subsequent anesthesia.
疑似围手术期过敏反应 (POP) 的患者需要进行彻底的调查,以确定潜在的触发因素,并为随后的手术提供安全的麻醉。POP 的流行病学变化引人注目。先前对 POP 发病率的估计范围在每 6000 至 20000 次麻醉之间,但来自法国和英国的最新数据表明,发病率估计为每 10000 次。其他重要变化包括众所周知的触发因素的等级发生变化,抗生素(β-内酰胺类)取代神经肌肉阻滞剂(NMB)成为 POP 的主要原因。洗必泰、专利蓝染料和替考拉宁作为重要触发因素的出现也是值得注意的发现。调查的主要依据是对过敏反应前事件时间线的关键分析,同时结合明智的皮肤测试。皮肤测试对于大多数药物/试剂的未知预测值存在局限性,因此,了解健康对照者的背景阳性率、个体药物的测试特征以及使用非刺激性浓度对于避免假阳性和假阴性结果至关重要。针对个体药物的特异性 IgE 检测仅适用于有限数量的药物,不能替代皮肤测试。急性血清总类胰蛋白酶在 IgE 介导的 POP 过敏反应中具有高特异性和阳性预测值,但受到其中度敏感性和阴性预测值的限制。在这群患者中计划安全麻醉特别具有挑战性,因此麻醉师需要警惕过敏反应再次发作的可能性。由于目前对 POP 的调查存在局限性,因此系统地收集关于重复麻醉结果的数据对于验证当前的调查方法非常有价值。本文回顾了 POP 的流行病学变化,参考了主要的触发因素,以及随后麻醉的调查和结果。